Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ISB2001 A Groundbreaking Trispecific Antibody Shows Promise for ...
CISCO ISB2001 T-home beltéri távirányító - eMAG.hu
Самоинсталација на дополнителен Cisco ISB2001 рисивер на бакарен медиум ...
Ichnos Glenmark于《Nature Cancer》发布首款BCMA/CD38/CD3三特异性抗体ISB 2001的临床前研究数据 - 知乎
Join us at #COMy2025 for ISB 2001 Oral Presentation. | Lida Pacaud, M.D.
Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology ...
ISB 2001 - oral - FINAL for ASH upload.pdf | IGI
ISB 2001 is our first-in-class T cell-engaging trispecific antibody in ...
05 May 2025: FDA Grants Fast Track Designation to ISB 2001 for Relapsed ...
ISB 2001 Shows Promising Results in Treating Multiple Myeloma Patients ...
ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager ...
🧬 Glenmark’s ISB 2001 Delivers 79% Response Rate in Phase 1 — A New ...
ISB 2001 三特异性 T 细胞接合器显示出强肿瘤细胞毒性并克服多发性骨髓瘤细胞的免疫逃逸机制,Nature Cancer - X-MOL
FDA Fast Tracks ISB 2001 for RRMM patients | Shweta Munjal posted on ...
Pipeline - Ichnos Glenmark Innovation
Anti-CD38 + BCMA + CD3 epsilon Bispecific Antibody [ISB2001] (A341069)
FDA Issues Fast Track Designation to First-In-Class Trispecific ...
Full Dose-Escalation Data Show Continued High Response Rates and ...
【🦾19 億美元豪擲！艾伯維再掃「三特異」血癌新星 BCMA/CD38/CD3 三抗 ISB-2001 強勢登場】 - 藥時事 ...
Glenmark’s US Alliance Ichnos Glenmark Innovation to Present Phase 1 ...
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global
Glenmark Ichnos Sciences Exhibits Early-Stage Results of Cancer Drug ...
Ichnos Glenmark’s ISB 2001 Shows Promising Results in Phase 1 Myeloma Trial
ISB 2001 is a new clinical trial for multiple myeloma | Ichnos Glenmark ...
CD38 | MCE 生命科学试剂服务商
ISB2001-hIgG1 - Kyinno Bio
Glenmark and AbbVie Join Forces for Cancer Treatment Breakthrough with ...
Ichnos Glenmark's ISB 2001 Shows Promising Phase 1 Trial Results for ...
ISB 2001: Accelerating Patient Benefits through Quantitative Systems ...
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track ...
19.25亿美元！艾伯维引进一款CD3/CD38/BCMA三特异性抗体医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
A Phase I, first-in-human study of ISB 2001 in R/R myeloma: dose ...
ISB 2001 Shows High Response Rates in Relapsed/Refractory Multiple Myeloma
FDA Grants ISB 2001 Fast Track Designation in RRMM
Frontiers | Design of a Trispecific Checkpoint Inhibitor and Natural ...
AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001 ...
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global ...
Full dose escalation data show favorable safety profile of ISB 2001 for ...
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple ...
isb_2001___ichnos_sciences__(sub) (Original)
📣 AbbVieが7億ドルでトライスペシフィック抗体ISB 2001を獲得‼️ | Miki Nonaka-Kinoshita, Ph.D.
Licensing deal for cancer drug candidate ISB 2001, shortly: Glenmark ...
FDA Fast Track Trispecific for R/R Myeloma - HealthTree for Multiple ...
Glenmark Pharma's ISB 2001: A Trispecific Breakthrough in Multiple ...
FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma
ISB-2001(ISB-2001) - 药物靶点：BCMA x CD3 x CD38_在研适应症：难治性多发性骨髓瘤，复发性多发性骨髓瘤 ...
ISB 2001 Yields New Prospects as Multiple Myeloma Treatment | Blood ...
IGI's new drug ISB 2001 shows promise in treating multiple Myeloma ...
Glenmark expects ISB 2001 deal with AbbVie to close in September - The ...
The first results of ISB 2001, a BCMAxCD38xCD3 targeting trispecific ...
AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+
This trial site initiation and advancement of the clinical study of ISB ...
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach ...
Optimizing First-In-Human Doses for Tri-specific Antibodies in Oncology
Schematic representation and characterization of trispecific T-cell ...
Cummins ISB ESN #56806041 2001 Used Engine – Young and Sons
Glenmark to retain ISB 2001 rights in India, emerging markets; AbbVie ...
#ash24 | IGI
Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal | BioWorld
Bassists of Bill Evans -- ISB 2001 Tribute to Scott LaFaro -- Photos
AbbVie Licenses IGI Therapeutics' ISB 2001 for Oncology and Autoimmune ...
Ichnos Glenmark Innovation Shares Promising Clinical Data from Phase 1 ...
FDA grants orphan drug designation to ISB 2001
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting ...
Ichnos Glenmark ISB 2001: Ichnos Glenmark Drug ISB 2001 shows overall ...
报告封面
554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a ...
ISB 2001 三特异性 T 细胞衔接器显示出强大的肿瘤细胞毒性，并克服多发性骨髓瘤细胞的免疫逃逸机制 | Certara
Glenmark Hits 10% Upper Circuit on $2B AbbVie Cancer Deal
ISB 2001-101 – Blood Cancer Research WA
Highlights of our most recent quarter reflect the announcement of the ...
Glenmark’s blood cancer drug ISB 2001 shows promising results in trial ...
Ichnos Glenmark Innovation and AbbVie Announce Exclusive Global ...
从实验室到临床 | 揭开三特异抗体研发的创新之钥
Glenmark, AbbVie Ink Licensing Deal for ISB 2001: Rediff Moneynews
Cummins ISB, 2001, Opa Locka, Florida, United States - Mascus engines
FDA Grants Fast Track Status to IGI's ISB 2001 for Difficult-to-Treat ...
FDA Fast Track Designation for ISB 2001 for R/R Multiple Myeloma
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...
Our trispecific T-cell engager model was designed through a rigorous ...
Glenmark Pharma shares cool off after hitting 20% upper circuit post ...
Week 1, May 2025: Progress in BCMA-Targeted Therapies
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of ...
Glenmark Pharma Presents First Clinical Data From Phase 1 Study For ...
Week 1, August 2025: Renewing Hope with Trispecific Antibodies
And we turn a year wiser today! ISB was inaugurated on Dec 2, 2001, by ...
C8300 Hardware Installation Guide at Brooke Way blog
ISB scholarship student gains perfect score - The Bruneian
79%患者肿瘤显著缩小或完全消失！美国新药ISB 2001治疗复发/难治性骨髓瘤疗效强劲-出国看病-盛诺一家
IGI
Unveiling the Wiring Diagram for Cummins ISB ECM - WireMystique
